> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Thermo Fisher's $244 Million Plant-Sale Loss Nearly Wipes Out Its $72 Million Microbiology Gain
- URL: https://www.bullished.co/thermo-fishers-244-million-plant-sale-loss-nearly-wipes-out-its-72-million-microbiology-37a915f9/
- Published: 2026-10-30T15:06:10.000Z
- Updated: 2026-10-30T15:06:10.000Z
- Description: A held-for-sale loss on a drug-manufacturing site offset the microbiology sale gain as 2026 severance actions reached about 2% of staff.
- Author: Matteo Parrino
- Tags: SEC Filings, TMO, Industry: Healthcare

[Thermo Fisher Scientific](https://www.bullished.co/tag/tmo/) booked a [$244 million held-for-sale loss](https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000179/tmo-20260926.htm?ref=bullished.co) in the third quarter on a deal to sell a pharma services manufacturing plant, a hit that outweighs the $72 million pre-tax gain from selling its microbiology business, according to its 10-Q filed Friday. The company, which supplies lab instruments, reagents, diagnostics and outsourced drug development services, also said severance actions this year now touch about 2% of its workforce.

## Two divestitures, opposite results

On September 4, the company agreed to sell a pharma services manufacturing facility, along with its customer contracts and employees, out of the Laboratory Products and Biopharma Services segment. It took the $244 million loss in the quarter.

Astorg bought the microbiology unit on August 12 for roughly $1.07 billion, paid partly in cash and partly via a promissory note, producing a $72 million pre-tax gain. The business sat in Specialty Diagnostics, whose third-quarter revenue slid to $1,098 million from $1,174 million a year earlier. The [second-quarter report](https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000144/tmo-20260627.htm?ref=bullished.co) had carried the microbiology sale as pending, with a $60 million impairment as the main charge.

Third-quarter restructuring and other costs totaled $199 million. Laboratory Products and Biopharma Services bore $256 million, while Specialty Diagnostics showed a $(60) million credit from the gain.

## Layoffs widen, charges shrink

Severance actions tied to facility consolidations and cost cuts affected about 2% of the workforce in 2026, against about 1% in the second-quarter filing. The company has identified further actions, mostly in Laboratory Products and Biopharma Services, that it expects will cost about $180 million, primarily in 2026, down from about $220 million at the prior report. It expects to identify more actions in future periods.

The broader quarter was solid. Revenue grew 9% to $12,137 million, and GAAP operating income rose 17% to $2,263 million, according to the [earnings release](https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000173/q32026earnings8kex99%5F1.htm?ref=bullished.co) issued October 21\. Adjusted operating income, which excludes the sale gain and the loss, rose 15% to $2,968 million.

## Debt-funded growth and a December maturity

Cash and equivalents fell to $5.46 billion from $9.85 billion at the start of the year, and total debt rose to $41.37 billion from $39.38 billion. Net interest expense climbed to $165 million in the quarter from $113 million, which the 10-Q attributes to added debt funding buybacks, dividends and the Clario purchase.

In the first nine months the company repurchased $4.00 billion of stock, and $1.00 billion remains under its authorization. A $1.00 billion senior note, carrying a 5.00% coupon, is due December 5, 2026\. Remaining performance obligations on open customer contracts stood at $29.87 billion at September 26, about 52% of which the company expects to recognize within twelve months.

The $1.00 billion note due December 5 is the next hard date on the company's debt schedule.

### Sources

- [10-Q Filing — Thermo Fisher Scientific (TMO)](https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000179/tmo-20260926.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Thermo Fisher Scientific (TMO), Q2 FY2026 filed 2026-07-31 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000144/tmo-20260627.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, q32026earnings8kex99\_1.htm) — Thermo Fisher Scientific, filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000173/q32026earnings8kex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Is Thermo Fisher Scientific (TMO) Fully Priced On Its Latest Results?](https://sg.finance.yahoo.com/news/thermo-fisher-scientific-tmo-fully-043150261.html?ref=bullished.co) — Yahoo Finance
- [Thermo Fisher Scientific Inc (TMO) Stock Forecasts](https://finance.yahoo.com/research/reports/ARGUS%5F48653%5FStockPicks%5F1793016250000?ref=bullished.co) — Yahoo Finance
- [Thermo Fisher Scientific (TMO) Lands Spotlight In Fast Growing Cell And Gene Therapy CRO Market](https://uk.finance.yahoo.com/news/thermo-fisher-scientific-tmo-lands-102126140.html?ref=bullished.co) — Yahoo Finance
- [Thermo Fisher (TMO) Stock Could Trade At A Premium On Strong Q3 Results](https://sg.finance.yahoo.com/news/thermo-fisher-tmo-stock-could-030955050.html?ref=bullished.co) — Yahoo Finance
- [Analyst Observations | Nasdaq Dorsey Wright](https://dorseywright.nasdaq.com/research/bigwire/2026/10/28/10-28-2026/analyst-observations?ref=bullished.co) — dorseywright.nasdaq.com

### More on Thermo Fisher Scientific

- [Thermo Fisher's Tariff Refunds Supplied 15 Cents Of Third-Quarter EPS, Biggest Piece Of Beat](https://www.bullished.co/thermo-fishers-tariff-refunds-supplied-15-cents-of-third-quarter-eps-biggest-piece-of-beat-4a2c092c/)
- [Thermo Fisher Adjusted EPS Rises 15% To $6.68 As Operating Margin Widens To 24.5%](https://www.bullished.co/thermo-fisher-adjusted-eps-rises-15-to-6-68-as-operating-margin-widens-to-24-5-3faea7f8/)

[All Thermo Fisher Scientific (TMO) coverage →](https://www.bullished.co/tag/tmo/)